August 2012
-
Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis… Read more . . .
-
Retrophin has announced that Stephen Aselage will take over as interim CEO immediately, replacing company founder and CEO Martin Shkreli. According to reports, Shkreli was fired for “stock trading irregularities” and other rules violations. Aselage… Read more . . .
-
Twenty-five years after its first meeting in a Glaxo Group Research lecture theater, the Aerosol Society’s annual Drug Delivery to the Lungs conference marks its silver anniversary with DDL 25, taking place December 10-12 at… Read more . . .
-
Boehringer Ingelheim has announced that it will spend over €100 million to increase production capacity for the Respimat inhaler at its Dortmund, Germany site to 44 million units per year. In addition, the company said,… Read more . . .
-
According to Lightlake Therapeutics, an investor will receive a 0.98% interest in the company’s naloxone nasal spray for the treatment of opioid overdose for a $500,000 investment and a 1% interest in intranasal naloxone for… Read more . . .
-
Discovery Laboratories has received a Phase 2 Small Business Innovation Research Grant (SBIR) from the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) for development of aerosolized KL4 surfactant for… Read more . . .
-
Sunovion Pharmaceuticals has announced that it will sell “certain rights” to its Xopenex levalbuterol inhalation solution to Akorn for $45 million. Rights to the Xopenex HFA MDI are being retained by Sunovion. Akorn says that… Read more . . .
-
Verona Pharma says that the company will present data at the upcoming North American Cystic Fibrosis Conference showing that its RPL554 inhaled PDE3/PDE4 inhibitor could be useful in treating CF. According to the company, “The… Read more . . .
-
Consort Medical, the parent company of device supplier Bespak, has announced that it will acquire CDMO Aesica Pharmaceuticals for £230 million, with the deal expected to be complete in November, 2014. Aesica offers development and… Read more . . .
-
Almirall has announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the company’s aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. Almirall will market the product as… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland